Compare Stocks: CERS, AVNS, QDEL, and SMTI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVNS Avanos Medical	$24.99	$24.95	$9.30 ▼ $25.49	$1.17B	1.57	700,357 shs	N/A
CERS Cerus	$2.19 +1.9%	$2.84	$1.15 ▼ $3.47	$433.28M	1.81	2.44 million shs	6.25 million shs
QDEL QuidelOrtho	$17.58 -0.7%	$15.60	$9.92 ▼ $35.58	$1.21B	0.68	1.12 million shs	1.18 million shs
SMTI Sanara MedTech	$34.06 +0.2%	$24.50	$16.05 ▼ $35.95	$311.58M	1.13	281,157 shs	232,099 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVNS Avanos Medical	0.00%	0.00%	+0.26%	+1.08%	+121.54%
CERS Cerus	+1.86%	-25.00%	-30.70%	-15.44%	+68.46%
QDEL QuidelOrtho	-0.73%	+5.46%	-3.67%	+60.40%	-27.08%
SMTI Sanara MedTech	+0.18%	+27.85%	+37.12%	+77.86%	+37.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVNS Avanos Medical	$24.99	$24.95	$9.30 ▼ $25.49	$1.17B	1.57	700,357 shs	N/A
CERS Cerus	$2.19 +1.9%	$2.84	$1.15 ▼ $3.47	$433.28M	1.81	2.44 million shs	6.25 million shs
QDEL QuidelOrtho	$17.58 -0.7%	$15.60	$9.92 ▼ $35.58	$1.21B	0.68	1.12 million shs	1.18 million shs
SMTI Sanara MedTech	$34.06 +0.2%	$24.50	$16.05 ▼ $35.95	$311.58M	1.13	281,157 shs	232,099 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVNS Avanos Medical	0.00%	0.00%	+0.26%	+1.08%	+121.54%
CERS Cerus	+1.86%	-25.00%	-30.70%	-15.44%	+68.46%
QDEL QuidelOrtho	-0.73%	+5.46%	-3.67%	+60.40%	-27.08%
SMTI Sanara MedTech	+0.18%	+27.85%	+37.12%	+77.86%	+37.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVNS Avanos Medical	1.50	Reduce	N/A	N/A
CERS Cerus	2.25	Hold	$4.00	82.65% Upside
QDEL QuidelOrtho	1.67	Reduce	$13.63	-22.50% Downside
SMTI Sanara MedTech	1.80	Reduce	$35.00	2.76% Upside

Current Analyst Ratings Breakdown

Latest CERS, AVNS, QDEL, and SMTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	SMTI Sanara MedTech	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/30/2026	SMTI Sanara MedTech	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$35.00
7/30/2026	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$36.00 ➝ $35.00
7/20/2026	AVNS Avanos Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	QDEL QuidelOrtho	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	SMTI Sanara MedTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	QDEL QuidelOrtho	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$13.00 ➝ $18.00
7/1/2026	QDEL QuidelOrtho	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$11.00 ➝ $12.00
6/29/2026	QDEL QuidelOrtho	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
6/18/2026	CERS Cerus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/17/2026	SMTI Sanara MedTech	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVNS Avanos Medical	$715.90M	1.64	$3.42 per share	7.30	$16.73 per share	1.49
CERS Cerus	$206.13M	2.14	N/A	N/A	$0.35 per share	6.26
QDEL QuidelOrtho	$2.73B	0.44	$18.70 per share	0.94	$28.27 per share	0.62
SMTI Sanara MedTech	$103.12M	3.03	$0.60 per share	57.19	$0.67 per share	50.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVNS Avanos Medical	-$72.90M	-$1.61	N/A	26.59	N/A	-10.39%	5.39%	3.97%	8/10/2026 (Estimated)
CERS Cerus	-$15.63M	-$0.03	N/A	N/A	N/A	-3.06%	-10.19%	-3.14%	N/A
QDEL QuidelOrtho	-$1.13B	-$17.82	N/A	7.48	N/A	-45.57%	4.25%	1.56%	8/6/2026 (Estimated)
SMTI Sanara MedTech	-$37.56M	-$3.77	N/A	N/A	N/A	-31.23%	-3.19%	-0.56%	8/12/2026 (Estimated)

Latest CERS, AVNS, QDEL, and SMTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	SMTI Sanara MedTech	-$0.0250	N/A	N/A	N/A	$28.95 million	N/A
8/10/2026	Q2 2026	AVNS Avanos Medical	$0.16	N/A	N/A	N/A	$173.00 million	N/A
8/6/2026	Q2 2026	QDEL QuidelOrtho	-$0.04	N/A	N/A	N/A	$618.72 million	N/A
7/30/2026	Q2 2026	CERS Cerus	-$0.0133	-$0.01	+$0.0033	-$0.01	$62.90 million	$63.30 million
5/5/2026	Q1 2026	AVNS Avanos Medical	$0.16	$0.22	+$0.06	$0.11	$170.00 million	$182.20 million
5/5/2026	Q1 2026	QDEL QuidelOrtho	$0.37	-$0.04	-$0.41	-$1.35	$665.23 million	$619.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVNS Avanos Medical	N/A	N/A	N/A	N/A	N/A
CERS Cerus	N/A	N/A	N/A	N/A	N/A
QDEL QuidelOrtho	N/A	N/A	N/A	N/A	N/A
SMTI Sanara MedTech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVNS Avanos Medical	0.11	2.48	1.40
CERS Cerus	0.49	1.83	1.07
QDEL QuidelOrtho	1.33	1.43	0.80
SMTI Sanara MedTech	6.59	2.28	2.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVNS Avanos Medical	95.17%
CERS Cerus	78.37%
QDEL QuidelOrtho	99.00%
SMTI Sanara MedTech	8.10%

Insider Ownership

Company	Insider Ownership
AVNS Avanos Medical	2.33%
CERS Cerus	5.30%
QDEL QuidelOrtho	1.10%
SMTI Sanara MedTech	42.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVNS Avanos Medical	2,287	46.85 million	45.76 million	Optionable
CERS Cerus	290	201.52 million	190.84 million	Optionable
QDEL QuidelOrtho	6,500	68.19 million	67.44 million	Optionable
SMTI Sanara MedTech	60	9.16 million	5.32 million	Not Optionable

CERS, AVNS, QDEL, and SMTI Headlines

Recent News About These Companies

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—FBRX, LXFR, SMTI, and MKTX

August 4 at 12:35 PM | globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ), Sanara MedTech Inc. (Nasdaq – SMTI), TriCo Bancshares (Nasdaq – TCBK)

August 4 at 11:22 AM | globenewswire.com

Sanara MedTech (NASDAQ:SMTI) Stock Rating Lowered by Freedom Capital

August 4 at 5:59 AM | marketbeat.com

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

August 3 at 4:19 PM | businesswire.com

Sanara MedTech (NASDAQ:SMTI) Cut to Neutral at HC Wainwright

August 2 at 1:48 AM | americanbankingnews.com

Wall Street Zen Downgrades Sanara MedTech (NASDAQ:SMTI) to Buy

August 1, 2026 | americanbankingnews.com

Sanara MedTech (NASDAQ:SMTI) Downgraded by Wall Street Zen to Buy

August 1, 2026 | marketbeat.com

MiMedx to acquire Sanara MedTech for $350M

July 31, 2026 | massdevice.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sanara MedTech Inc. (NASDAQ: SMTI)

July 30, 2026 | prnewswire.com

July 30, 2026 | globenewswire.com

Sanara MedTech (NASDAQ:SMTI) Downgraded to Neutral Rating by HC Wainwright

July 30, 2026 | marketbeat.com

Shareholder Alert: Ademi LLP investigates whether Sanara MedTech Inc. is obtaining a Fair Price for Public Shareholders

July 30, 2026 | prnewswire.com

SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders

July 30, 2026 | aol.comA

MiMedx agrees to buy Sanara MedTech for $35 a share

July 30, 2026 | msn.com

Sanara MedTech agrees to be acquired by MiMedx

July 29, 2026 | tipranks.com

MIMEDX to Acquire Sanara MedTech

July 29, 2026 | globenewswire.com

Sanara MedTech Inc. (NASDAQ:SMTI) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 13, 2026 | marketbeat.com

Sanara MedTech (SMTI) Stock Gets Fair Value Bump As Analysts Back Wound Care Growth

June 23, 2026 | finance.yahoo.com

Sanara MedTech Earnings Call Signals Profitable Growth

June 12, 2026 | theglobeandmail.com

Sanara MedTech (SMTI) Q1 2026 Earnings Transcript

June 2, 2026 | fool.com

How The Sanara MedTech (SMTI) Narrative Is Shifting As The US$34 Target Stays Put

May 23, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS, AVNS, QDEL, and SMTI Company Descriptions

Avanos Medical NYSE:AVNS

$24.99 0.00 (0.00%)

As of 08/3/2026

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Cerus NASDAQ:CERS

$2.19 +0.04 (+1.86%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$2.19 0.00 (-0.18%)

As of 07:50 AM Eastern

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

QuidelOrtho NASDAQ:QDEL

$17.58 -0.13 (-0.73%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$17.50 -0.08 (-0.45%)

As of 07:01 AM Eastern

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Sanara MedTech NASDAQ:SMTI

$34.06 +0.06 (+0.18%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$33.69 -0.37 (-1.08%)

As of 08:12 AM Eastern

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CERS, AVNS, QDEL, and SMTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CERS, AVNS, QDEL, and SMTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CERS, AVNS, QDEL, and SMTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS, AVNS, QDEL, and SMTI Company Descriptions

Avanos Medical NYSE:AVNS

Cerus NASDAQ:CERS

QuidelOrtho NASDAQ:QDEL

Sanara MedTech NASDAQ:SMTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CERS, AVNS, QDEL, and SMTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CERS, AVNS, QDEL, and SMTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CERS, AVNS, QDEL, and SMTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS, AVNS, QDEL, and SMTI Company Descriptions

Avanos Medical NYSE:AVNS

Cerus NASDAQ:CERS

QuidelOrtho NASDAQ:QDEL

Sanara MedTech NASDAQ:SMTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools